Research Analysts Offer Predictions for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at Chardan Capital raised their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, May 13th. Chardan Capital analyst K. Nakae now anticipates that the biotechnology company will post earnings of ($1.27) per share for the year, up from their previous estimate of ($4.27). Chardan Capital has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same period in the prior year, the firm earned ($1.02) earnings per share.

Several other brokerages have also weighed in on ARWR. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup decreased their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. B. Riley reissued a “buy” rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $42.13.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $15.71 on Friday. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock’s fifty day moving average is $13.30 and its two-hundred day moving average is $17.79. The firm has a market capitalization of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the completion of the transaction, the chief executive officer now owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 275,880 shares of company stock worth $4,034,037. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. First Citizens Bank & Trust Co. purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $205,000. KBC Group NV grew its stake in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Pacer Advisors Inc. grew its stake in Arrowhead Pharmaceuticals by 11.6% during the 4th quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company’s stock worth $525,000 after purchasing an additional 2,907 shares in the last quarter. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,385 shares of the biotechnology company’s stock valued at $496,000 after purchasing an additional 2,475 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.